- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06913023
Semaglutide per la prevenzione del diabete mellito post-trapianto (SPOT-DM)
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Cheng Xu
- Numero di telefono: 8508 416-340-4800
- Email: cheng.xu@uhn.ca
Luoghi di studio
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Contatto:
- Vikas S Srinivasan, MD PhD FRCPC
- Numero di telefono: 604-806-8970
- Email: vikas.sridhar@phc.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2N2
- Toronto General Hospital
-
Contatto:
- Cheng Xu
- Numero di telefono: 8508 416-340-4800
- Email: cheng.xu@uhn.ca
-
Investigatore principale:
- Sunita Singh, MD MSc FRCPC
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Signed and dated written informed consent.
-
Adult (≥18 years) recipients of a living or deceased donor kidney transplant
-
Between 4- and 12-weeks post kidney transplant
-
Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)
-
At risk for PTDM at the time of transplant based on the following criteria:
- BMI ≥ 25 kg/m2, or
- Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
- 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
- HbA1C 5.5-6.4% (at risk for DM or prediabetes).
Exclusion Criteria:
- Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
- Kidney-Pancreas transplant recipient
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or MEN2B
- Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
- Use of GLP1RA in the 30 days prior to screening
- Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
- With known or suspected hypersensitivity to semaglutide or related products
- Patient not able to understand and comply with study requirements, based on Investigator's judgment.
- Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
- History of glucose-galactose malabsorption syndrome
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Semaglutide
Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant. |
Subcutaneous semaglutide 0.25mg for 4 weeks. Subcutaneous semaglutide 0.5mg for 4 weeks. Subcutaneous semaglutide 1.0 mg for 4 weeks. Subcutaneous semaglutide 1.7 mg for 4 weeks Subcutaneous semaglutide 2.4 mg for 8 weeks |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
2-hour OGTT
Lasso di tempo: 24 weeks
|
The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies. |
24 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pressione sanguigna sistolica
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Variazione del peso corporeo
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Modifica della circonferenza della vita
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Variazione dell'HbA1c
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Cambiamento del glicemia a digiuno
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Cambiamento nell'insulina sierica
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Modifica del profilo lipidico a digiuno
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Pressione sanguigna diastolica
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Pressione arteriosa media
Lasso di tempo: 24 settimane
|
24 settimane
|
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Lasso di tempo: 24 weeks
|
: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur. |
24 weeks
|
|
Estimated GFR
Lasso di tempo: 24 weeks
|
Calculated by CKD-EPI 2021 equation |
24 weeks
|
|
GFR
Lasso di tempo: 24 weeks
|
Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation. |
24 weeks
|
|
Albuminuria
Lasso di tempo: 24 weeks
|
measuring urine albumin excretion from a 24-hour urine collection |
24 weeks
|
|
Natriuresis
Lasso di tempo: 24 weeks
|
Assessed with a 24-hour urine collection for sodium excretion |
24 weeks
|
|
Percentage of body fat
Lasso di tempo: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
|
Change in liver enzymes
Lasso di tempo: 24 weeks
|
ALT and AST |
24 weeks
|
|
Change in fibrosis level
Lasso di tempo: 24 weeks
|
Transient elastography |
24 weeks
|
|
Change in steatosis level
Lasso di tempo: 24 weeks
|
Transient elastography |
24 weeks
|
|
Percentage of extracellular fluid
Lasso di tempo: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in kidney oxygenation (R2*)
Lasso di tempo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney fibrosis (ADC)
Lasso di tempo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney perfusion
Lasso di tempo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney volume
Lasso di tempo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney inflammation (T1)
Lasso di tempo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 25-5093
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .